课题基金 / 基金详情

Activity effects on Alzheimer neuropathology & dementia

Activity effects on Alzheimer neuropathology & dementia
活动对阿尔茨海默病神经病理学的影响
批准号:
6672745
负责人:
MICHAEL P MCDONALD
金额:
$29.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2007-07-31

项目摘要

项目成果

MICHAEL P MCDONALD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Epidemiological evidence suggests that ongoing mental or physical activity may attenuate the cognitive decline of Alzheimer's disease, or delay its onset. However, there are conflicting studies that do not show a benefit for increased cognitive activity or exercise for Alzheimer's patients. In addition, an alternate hypothesis suggests that some patients are predisposed to get Alzheimer's disease by early adulthood, and do not have the cognitive capacity or inclination to engage in mentally stimulating activity. The experiments proposed in this proposal are designed to establish cause-and-effect relationships between ongoing mental or physical activity and cognitive status in transgenic mice bearing the Swedish mutation of the amyloid precursor protein (APP). These transgenic mice develop Alzheimer-like amyloid plaques starting at approximately 10 months of age. When fed a folate-deficient diet supplemented with homocysteine for 3 months, APP transgenic mice, but not wild-type control mice, develop hippocampal-specific cell death. Thus we will be able to determine not only whether increased physical or mental activity improves cognitive performance but also whether it affects the rate of cell death or amyloid plaque formation, information that is not obtainable in human Alzheimer patients. Together, the data provided by the proposed experiments will inform us as to the potential effectiveness of cognitively stimulating activities or physical exercise as therapeutic or preventative measures in the fight against Alzheimer's disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of glycomacropeptide on memory and Alzheimer-related neuropathology
Dietary glycomacropeptide (GMP) for neuroprotection and cognitive enhancement
Dietary glycomacropeptide (GMP) for neuroprotection and cognitive enhancement
GD3 synthase gene therapy to improve memory and prevent neurodegeneration
海外基金